The study ultimately included 14 patients with confirmed EGFR mutations in NSCLC, all of whom received tyrosine kinase inhibitor (TKI) therapy (Table 1 and Fig. 3a). This evidence concerns the gene EGFR and non-small cell lung carcinoma.